z-logo
open-access-imgOpen Access
Optimization of payment for therapy with genetically engineered biological drugs and selective immunosuppressants at the expense of compulsory medical insurance fund in a day hospital at the regional level
Author(s) -
М. В. Сура,
T Boyarskaya,
E.V. Derkach
Publication year - 2021
Publication title -
medical technologies assessment and choice
Language(s) - English
Resource type - Journals
eISSN - 2712-7877
pISSN - 2219-0678
DOI - 10.17116/medtech20214303153
Subject(s) - payment , business , actuarial science , medical insurance , genetically engineered , health insurance , medicine , pharmacology , finance , economics , genetics , economic growth , gene , health care , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom